Heterocyclic-substituted bis-1,8 naphthalimide compounds, antibody drug conjugates, and methods of use
申请人:Gazzard J. Lewis
公开号:US20060182751A1
公开(公告)日:2006-08-17
The invention relates to bis 1,8 naphthalimide compounds including antibody drug conjugate (ADC) compounds represented by Formula I:
Ab-(L-D)
p
I
where one or more 1,8 bis-naphthalimide drug moieties (D) having Formulas IIa and IIb are covalently linked, through the wavy line, by a linker (L) to an antibody (Ab).
The invention also relates to heterocyclic-substituted 1,8 bis-naphthalimide compounds having Formula XV
The invention also relates to pharmaceutical compositions comprising an effective amount of a Formula I ADC or Formula XV heterocyclic-substituted 1,8 bis-naphthalimide compound for treatment of hyperproliferative disorders and other disorders. The invention also relates to methods for killing or inhibiting the proliferation of tumor cells or cancer cells including administering to a patient an effective amount of a Formula I ADC or Formula XV compound.
本发明涉及双 1,8-萘二甲酰亚胺化合物,包括由式 I 表示的抗体药物共轭物 (ADC) 化合物:
Ab-(L-D)
p
I
其中具有式 IIa 和 IIb 的一个或多个 1,8-双萘二亚胺药物分子(D)通过连接体 (L)与抗体(Ab)通过波浪线共价连接。
本发明还涉及具有式 XV 的杂环取代的 1,8 双萘二甲酰亚胺化合物。
本发明还涉及药物组合物,该药物组合物包含有效量的式ⅠADC或式XV杂环取代的1,8-双萘二亚胺化合物,用于治疗过度增殖性疾病和其他疾病。本发明还涉及杀死或抑制肿瘤细胞或癌细胞增殖的方法,包括向患者施用有效量的式ⅠADC或式XV化合物。